Skip to main content
SpringerLink
Log in

S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen

Zusammenfassung der Leitlinie der Deutschen Gesellschaft für Neurologie

S2k Guidelines: Diagnosis and Non-Interventional Treatment of Neuropathic Pain

Summary of the German Neurological Society guideline

  • Leitlinie
  • Published:
DGNeurologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Treede RD et al (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18):1630–1635

    CAS  PubMed  Google Scholar 

  2. van Hecke O et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155(4):654–662

    PubMed  Google Scholar 

  3. Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9(8):807–819

    PubMed  Google Scholar 

  4. Colloca L et al (2017) Neuropathic pain. Nat Rev Dis Primers 3:17002

    PubMed  PubMed Central  Google Scholar 

  5. van Hecke O et al (2015) Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations. Pain 156(11):2337–2353

    PubMed  PubMed Central  Google Scholar 

  6. Finnerup NB et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157(8):1599–1606

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Maier C et al (2010) Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150(3):439–450

    CAS  PubMed  Google Scholar 

  8. Westermann A et al (2011) Pain-associated mild sensory deficits without hyperalgesia in chronic non-neuropathic pain. Clin J Pain 27(9):782–789

    PubMed  Google Scholar 

  9. Backonja MM et al (2013) Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain 154(9):1807–1819

    PubMed  Google Scholar 

  10. Cruccu G et al (2010) EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 17(8):1010–1018

    CAS  PubMed  Google Scholar 

  11. Haanpaa M et al (2011) NeuPSIG guidelines on neuropathic pain assessment. Pain 152(1):14–27

    PubMed  Google Scholar 

  12. Lauria G et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 17(7):903–909

    CAS  PubMed  Google Scholar 

  13. Garcia-Larrea L et al (2002) Laser-evoked potential abnormalities in central pain patients: the influence of spontaneous and provoked pain. Brain 125(Pt 12):2766–2781

    PubMed  Google Scholar 

  14. Valeriani M et al (2012) Clinical usefulness of laser evoked potentials. Neurophysiol Clin 42(5):345–353

    CAS  PubMed  Google Scholar 

  15. Omori S et al (2017) Pain-related evoked potentials after intraepidermal electrical stimulation to Adelta and C fibers in patients with neuropathic pain. Neurosci Res 121:43–48

    PubMed  Google Scholar 

  16. Hansen N et al (2015) Amplitudes of pain-related evoked potentials are useful to detect small fiber involvement in painful mixed fiber neuropathies in addition to quantitative sensory testing—an Electrophysiological study. Front Neurol 6:244

    PubMed  PubMed Central  Google Scholar 

  17. Cruzat A, Qazi Y, Hamrah P (2017) In vivo confocal microscopy of corneal nerves in health and disease. Ocul Surf 15(1):15–47

    PubMed  Google Scholar 

  18. Ziegler D et al (2014) Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 63(7):2454–2463

    PubMed  Google Scholar 

  19. Chen X et al (2015) Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care 38(6):1138–1144

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Weidner C et al (2000) Acute effects of substance P and calcitonin gene-related peptide in human skin—a microdialysis study. J Invest Dermatol 115(6):1015–1020

    CAS  PubMed  Google Scholar 

  21. Fuller RW et al (1987) Sensory neuropeptide effects in human skin. Br J Pharmacol 92(4):781–788

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Kramer HH et al (2004) Electrically stimulated axon reflexes are diminished in diabetic small fiber neuropathies. Diabetes 53(3):769–774

    PubMed  Google Scholar 

  23. Bickel A et al (2009) C‑fiber axon reflex flare size correlates with epidermal nerve fiber density in human skin biopsies. J Peripher Nerv Syst 14(4):294–299

    CAS  PubMed  Google Scholar 

  24. Kalliomaki M et al (2011) Structural and functional differences between neuropathy with and without pain? Exp Neurol 231(2):199–206

    PubMed  Google Scholar 

  25. Schley M et al (2012) Skin innervation at different depths correlates with small fibre function but not with pain in neuropathic pain patients. Eur J Pain 16(10):1414–1425

    CAS  PubMed  Google Scholar 

  26. Bickel A et al (2002) Assessment of the neurogenic flare reaction in small-fiber neuropathies. Neurology 59(6):917–919

    CAS  PubMed  Google Scholar 

  27. Green AQ, Krishnan ST, Rayman G (2009) C‑fiber function assessed by the laser doppler imager flare technique and acetylcholine iontophoresis. Muscle Nerve 40(6):985–991

    PubMed  Google Scholar 

  28. Koppert W et al (2004) Mechanically induced axon reflex and hyperalgesia in human UV‑B burn are reduced by systemic lidocaine. Eur J Pain 8(3):237–244

    CAS  PubMed  Google Scholar 

  29. Krishnan ST, Rayman The LDIflare G (2004) The LDIflare: a novel test of C‑fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care 27(12):2930–2935

    PubMed  Google Scholar 

  30. Kubasch ML et al (2017) Laser doppler assessment of vasomotor axon reflex responsiveness to evaluate neurovascular function. Front Neurol 8:370

    PubMed  PubMed Central  Google Scholar 

  31. Unal-Cevik I (2018) Temporal and spatial quantification of pain-related small fiber functionality assessed using laser speckle contrast analysis. Pain Pract 18(7):824–838. https://doi.org/10.1111/papr.12679

    Article  PubMed  Google Scholar 

  32. Freynhagen R et al (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920

    PubMed  Google Scholar 

  33. Bouhassira D et al (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114(1–2):29–36

    PubMed  Google Scholar 

  34. Bennett M (2001) The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 92(1–2):147–157

    CAS  PubMed  Google Scholar 

  35. Bouhassira D et al (2004) Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108(3):248–257

    PubMed  Google Scholar 

  36. Galer BS, Jensen MP (1997) Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 48(2):332–338

    CAS  PubMed  Google Scholar 

  37. Chaparro LE et al (2012) Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008943.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wiffen PJ et al (2017) Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007938.pub4

    Article  PubMed  PubMed Central  Google Scholar 

  39. Finnerup NB et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162–173

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Waldfogel JM et al (2017) Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology 88(20):1958–1967

    CAS  PubMed  Google Scholar 

  41. Wiffen PJ et al (2014) Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005451.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  42. Griebeler ML et al (2014) Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med 161(9):639–649

    PubMed  Google Scholar 

  43. Thomas AM, Atkinson TJ (2018) Old friends with new faces: are sodium channel blockers the future of adjunct pain medication management? J Pain 19(1):1–9

    CAS  PubMed  Google Scholar 

  44. Zhou M et al (2017) Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007963.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  45. Snedecor SJ et al (2014) Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 14(2):167–184

    PubMed  Google Scholar 

  46. Demant DT et al (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155(11):2263–2273

    CAS  PubMed  Google Scholar 

  47. Sindrup SH et al (2017) Impact of etiology and duration of pain on pharmacological treatment effects in painful polyneuropathy. Eur J Pain 21(8):1443–1450

    CAS  PubMed  Google Scholar 

  48. Min K et al (2016) Symptom-based treatment of neuropathic pain in spinal Cord-injured patients: a randomized crossover clinical trial. Am J Phys Med Rehabil 95(5):330–338

    PubMed  Google Scholar 

  49. Holbech JV et al (2016) Pain phenotype as a predictor for drug response in painful polyneuropathy‑a retrospective analysis of data from controlled clinical trials. Pain 157(6):1305–1313

    CAS  PubMed  Google Scholar 

  50. Thienel U et al (2004) Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 110(4):221–231

    CAS  PubMed  Google Scholar 

  51. Wiffen PJ et al (2013) Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008314.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  52. Wiffen PJ et al (2013) Antiepileptic drugs for neuropathic pain and fibromyalgia—an overview of Cochrane reviews. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010567.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wiffen PJ, Derry S, Moore RA (2013) Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hearn L, Derry S, Moore RA (2012) Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009318.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  55. Birse F, Derry S, Moore RA (2012) Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009485.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  56. Saudek CD, Werns S, Reidenberg MM (1977) Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22(2):196–199

    CAS  PubMed  Google Scholar 

  57. Chadda VS, Mathur MS (1978) Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 26(5):403–406

    CAS  PubMed  Google Scholar 

  58. Moore RA et al (2015) Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008242.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  59. Derry S et al (2015) Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011209.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  60. Hearn L et al (2014) Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010769.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  61. Goldstein DJ et al (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116(1–2):109–118

    CAS  PubMed  Google Scholar 

  62. Raskin J et al (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6(5):346–356

    PubMed  Google Scholar 

  63. Wernicke JF et al (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67(8):1411–1420

    CAS  PubMed  Google Scholar 

  64. Sultan A et al (2008) Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 8:29

    PubMed  PubMed Central  Google Scholar 

  65. Ney JP et al (2013) Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med 14(5):706–719

    PubMed  Google Scholar 

  66. Kajdasz DK et al (2007) Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 29(Suppl):2536–2546

    CAS  PubMed  Google Scholar 

  67. Boyle J et al (2012) Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 35(12):2451–2458

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Lunn MP, Hughes RA, Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007115.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  69. Lindner V, Deuschl G (2004) Antidepressants and anticonvulsive agents. Practical utility profile in pain therapy. Schmerz 18(1):53–60

    CAS  PubMed  Google Scholar 

  70. Derry S et al (2015) Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011789

    Article  PubMed  PubMed Central  Google Scholar 

  71. Gallagher HC et al (2015) Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011091.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  72. Durand JP et al (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23(1):200–205

    CAS  PubMed  Google Scholar 

  73. Rowbotham MC et al (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110(3):697–706

    CAS  PubMed  Google Scholar 

  74. Sindrup SH et al (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60(8):1284–1289

    CAS  PubMed  Google Scholar 

  75. Attal N et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17(9):1113–e88

    CAS  PubMed  Google Scholar 

  76. Otto M et al (2008) Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 139(2):275–283

    CAS  PubMed  Google Scholar 

  77. Shimodozono M et al (2002) Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 112(10):1173–1181

    PubMed  Google Scholar 

  78. Sindrup SH et al (1992) The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 52(5):547–552

    CAS  PubMed  Google Scholar 

  79. Sindrup SH et al (1990) The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42(2):135–144

    CAS  PubMed  Google Scholar 

  80. Nishihara M et al (2013) Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician 16(5):E547–E552

    PubMed  Google Scholar 

  81. Moulin D et al (2014) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 19(6):328–335

    PubMed  PubMed Central  Google Scholar 

  82. Sommer C et al (2015) Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 29(1):35–46

    CAS  PubMed  Google Scholar 

  83. Duehmke RM et al (2017) Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003726.pub4

    Article  PubMed  PubMed Central  Google Scholar 

  84. Vinik AI et al (2014) A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 37(8):2302–2309

    CAS  PubMed  Google Scholar 

  85. Schwartz S et al (2015) A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig 35(2):95–108

    CAS  PubMed  Google Scholar 

  86. Cooper TE et al (2017) Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011669.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  87. Gaskell H et al (2016) Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010692.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  88. Stannard C et al (2016) Hydromorphone for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011604.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  89. Wiffen PJ et al (2015) Buprenorphine for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011603.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  90. McNicol ED, Ferguson MC, Schumann R (2017) Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012499.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  91. Derry S et al (2016) Fentanyl for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011605.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  92. Meng H et al (2017) Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg 125(5):1638–1652

    CAS  PubMed  Google Scholar 

  93. Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician 20(6):E755–E796

    CAS  PubMed  Google Scholar 

  94. Petzke F, Enax-Krumova EK, Hauser W (2016) Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz 30(1):62–88

    CAS  PubMed  Google Scholar 

  95. Iskedjian M et al (2007) Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23(1):17–24

    CAS  PubMed  Google Scholar 

  96. Hauser W, Petzke F, Fitzcharles MA (2018) Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management—An overview of systematic reviews. Eur J Pain 22(3):455–470

    CAS  PubMed  Google Scholar 

  97. Mucke M et al (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012182.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  98. Hauser W et al (2018) European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. https://doi.org/10.1002/ejp.1297

    Article  PubMed  Google Scholar 

  99. Cakici N et al (2016) Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med 33(11):1466–1476

    CAS  PubMed  Google Scholar 

  100.   Mijnhout GS et al (2012) Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. J Endocrinol. https://doi.org/10.1155/2012/456279

    Article  Google Scholar 

  101.   Ziegler D et al (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21(2):114–121

    CAS  PubMed  Google Scholar 

  102.   Dy SM et al (2017) AHRQ comparative effectiveness reviews. In: Preventing complications and treating symptoms of diabetic peripheral neuropathy. Agency for Healthcare Research and Quality, Rockville

    Google Scholar 

  103.   Ziegler D et al (2011) Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34(9):2054–2060

    CAS  PubMed  PubMed Central  Google Scholar 

  104.   Aiyer R et al (2018) A systematic review of NMDA receptor antagonists for treatment of Neuropathic pain in clinical practice. Clin J Pain 34(5):450–467

    PubMed  Google Scholar 

  105.   Cvrcek P (2008) Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 9(2):253–257

    PubMed  Google Scholar 

  106.   Eide PK, Stubhaug A, Stenehjem AE (1995) Central dysesthesia pain after traumatic spinal cord injury is dependent on N‑methyl-D-aspartate receptor activation. Neurosurgery 37(6):1080–1087

    CAS  PubMed  Google Scholar 

  107.   Vo T, Rice AS, Dworkin RH (2009) Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 143(3):169–171

    PubMed  Google Scholar 

  108.   Moore RA et al (2015) Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010902.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  109.   Wiffen PJ et al (2016) Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012227.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  110.   Corrigan R et al (2012) Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009486.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  111.   Baron R et al (2009) 5 % lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 25(7):1663–1676

    CAS  PubMed  Google Scholar 

  112.   Derry S et al (2014) Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010958.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  113.   Navez ML et al (2015) 5 % Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability. Pain Ther 4(1):1–15

    PubMed  PubMed Central  Google Scholar 

  114.   Derry S et al (2017) Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007393.pub3

    Article  PubMed  PubMed Central  Google Scholar 

  115.   Mou J et al (2013) Efficacy of Qutenza (R) (capsaicin) 8 % patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain 154(9):1632–1639

    CAS  PubMed  Google Scholar 

  116.   van Nooten F et al (2017) Capsaicin 8 % patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther 39(4):787–803

    PubMed  Google Scholar 

  117.   Park J, Park HJ (2017) Botulinum toxin for the treatment of neuropathic pain. Toxins. https://doi.org/10.3390/toxins9090260

    Article  PubMed  PubMed Central  Google Scholar 

  118.   Lakhan SE, Velasco DN, Tepper D (2015) Botulinum toxin‑A for painful diabetic neuropathy: a meta-analysis. Pain Med 16(9):1773–1780

    PubMed  Google Scholar 

  119.   Shackleton T et al (2016) The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses. Oral Surg Oral Med Oral Pathol Oral Radiol 122(1):61–71

    PubMed  Google Scholar 

  120.   Attal N et al (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 15(6):555–565

    CAS  PubMed  Google Scholar 

  121.   Thompson DF, Brooks KG (2015) Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther 40(5):496–503

    CAS  PubMed  Google Scholar 

  122.   Ho KY et al (2008) Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain 24(1):51–55

    PubMed  Google Scholar 

  123.   Gibson W, Wand BM, O’Connell NE (2017) Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011976.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  124.   Eccleston C, Hearn L, Williams AC (2015) Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011259.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  125.   Heutink M et al (2012) The CONECSI trial: results of a randomized controlled trial of a multidisciplinary cognitive behavioral program for coping with chronic neuropathic pain after spinal cord injury. Pain 153(1):120–128

    PubMed  Google Scholar 

  126.   Miziara ID et al (2009) Group psychotherapy: an additional approach to burning mouth syndrome. J Psychosom Res 67(5):443–448

    PubMed  Google Scholar 

  127.   Arnold B et al (2014) Multimodal pain therapy for treatment of chronic pain syndrome. Consensus paper of the ad hoc commission on multimodal interdisciplinary pain management of the German Pain Society on treatment contents. Schmerz 28(5):459–472

    CAS  PubMed  Google Scholar 

  128.   Heutink M et al (2014) Long-term outcomes of a multidisciplinary cognitive behavioural programme for coping with chronic neuropathic spinal cord injury pain. J Rehabil Med 46(6):540–545

    PubMed  Google Scholar 

  129.   Burns AS et al (2013) Evaluation of an interdisciplinary program for chronic pain after spinal cord injury. PM R 5(10):832–838

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fachbereich Neurologie, DKD Helios Klinik Wiesbaden, Aukammallee 33, 65191, Wiesbaden, Deutschland

    Tanja Schlereth

Authors
  1. Tanja Schlereth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tanja Schlereth.

Ethics declarations

Interessenkonflikt

T. Schlereth gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

P. Berlit, Berlin

Federführende Fachgesellschaft

Deutsche Gesellschaft für Neurologie (DGN)

Federführend

PD Dr. med. Tanja Schlereth, Wiesbaden

Die vollständige Leitlinie wurde unter https://www.dgn.org/leitlinien/3805-ll-030-114-diagnose-und-nicht-interventionelle-therapie-neuropathischer-schmerzen-2019 am 04.09.2019 publiziert.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schlereth, T. S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen. DGNeurologie 3, 21–40 (2020). https://doi.org/10.1007/s42451-019-00139-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42451-019-00139-8

Search

Navigation